#1 Clinical Trials Search in Europe

Ivospemin

A new drug called Ivospemin, also known as SBP-101, is currently being studied in clinical trials for the treatment of metastatic pancreatic ductal adenocarcinoma. This article provides information about the ongoing research, including the drug’s potential benefits, how it’s being tested, and what patients might expect from participating in the trial.

Table of Contents

What is IVOSPEMIN?

IVOSPEMIN, also known by its product code SBP-101, is a new medication being studied for the treatment of metastatic pancreatic ductal adenocarcinoma, a severe form of pancreatic cancer that has spread to other parts of the body[1]. It is classified as a small molecule and polyamine metabolic inhibitor, which means it works by interfering with certain processes in cancer cells[1].

Medical Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic pancreatic ductal adenocarcinoma is a type of pancreatic cancer that has spread beyond the pancreas to other parts of the body. It is a serious and life-threatening condition that often requires aggressive treatment[1].

Clinical Trial Overview

A clinical trial is currently underway to evaluate the effectiveness of IVOSPEMIN in treating metastatic pancreatic ductal adenocarcinoma. This study is a randomized, double-blind, placebo-controlled trial, which means that participants are randomly assigned to receive either IVOSPEMIN or a placebo, and neither the patients nor the doctors know who is receiving which treatment[1].

How IVOSPEMIN Works

IVOSPEMIN is administered through subcutaneous injection, which means it is injected just under the skin. It is designed to work as a polyamine metabolic inhibitor, potentially interfering with processes that cancer cells need to grow and survive[1].

Eligibility Criteria

To participate in this study, patients must meet certain criteria, including:

  • Having a confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma
  • Being previously untreated for this condition
  • Being at least 18 years old
  • Having adequate bone marrow, liver, kidney, and blood clotting function
  • Having a life expectancy of at least 3 months

There are also some conditions that would exclude a person from participating, such as:

  • Having known BRCA1/2 gene mutations
  • Taking metformin (a diabetes medication)
  • Being pregnant or breastfeeding
  • Having had major surgery within 4 weeks of starting the study treatment

It’s important to note that these are just some of the criteria, and a healthcare provider would need to do a full evaluation to determine if someone is eligible for the study[1].

Treatment Combination

In this study, IVOSPEMIN is being tested in combination with two other cancer drugs: nab-paclitaxel and gemcitabine. These are standard treatments for metastatic pancreatic cancer. The study aims to see if adding IVOSPEMIN to this combination improves outcomes for patients[1].

Study Objectives

The main goal of this study is to compare overall survival between patients who receive IVOSPEMIN and those who receive a placebo, when combined with nab-paclitaxel and gemcitabine. Overall survival refers to how long patients live after starting the treatment[1].

Secondary objectives include comparing:

  • Progression-free survival: The time until the cancer starts growing again or the patient dies
  • Objective response rate: The percentage of patients whose tumors shrink or disappear
  • Disease control rate: The percentage of patients whose disease doesn’t worsen
  • Duration of response: How long the cancer remains controlled
  • Quality of life: How the treatment affects patients’ overall well-being
  • Safety and tolerability of IVOSPEMIN compared to placebo

Potential Benefits

If successful, IVOSPEMIN could potentially offer several benefits for patients with metastatic pancreatic ductal adenocarcinoma:

  • Improved survival rates
  • Better control of cancer growth
  • Improved quality of life
  • A new treatment option for a difficult-to-treat cancer

However, it’s important to remember that these potential benefits are still being studied and are not guaranteed[1].

Safety Considerations

As with any new medication, safety is a key concern. The study is carefully monitoring patients for any side effects or adverse reactions. Some specific safety considerations include:

  • Monitoring of bone marrow, liver, and kidney function
  • Regular heart rhythm checks (ECG)
  • Careful screening for any conditions that might make the treatment unsafe

Patients in the study are closely monitored by healthcare professionals to ensure their safety throughout the trial[1].

Aspect Details
Drug Name Ivospemin (SBP-101)
Condition Studied Metastatic Pancreatic Ductal Adenocarcinoma
Study Type Randomized, Double-Blind, Placebo-Controlled
Treatment Combination Ivospemin + Nab-paclitaxel + Gemcitabine
Primary Objective Compare overall survival between Ivospemin and placebo groups
Secondary Objectives Progression-free survival, Objective response rate, Disease control rate, Duration of response, Quality of life changes
Exploratory Measures Effects on CA19-9 and circulating tumor DNA levels
Key Eligibility Criteria Adults with confirmed metastatic pancreatic ductal adenocarcinoma, previously untreated for metastatic disease
Drug Characteristics Small molecule, polyamine metabolic inhibitor
Administration Route Subcutaneous injection

FAQ

  • What is Ivospemin (SBP-101)? Ivospemin, also known as SBP-101, is a new drug being tested for treating metastatic pancreatic ductal adenocarcinoma. It's a small molecule that works as a polyamine metabolic inhibitor, which means it may help slow down or stop cancer growth.
  • How is Ivospemin being tested in clinical trials? Ivospemin is being tested in a randomized, double-blind, placebo-controlled study. This means some patients receive Ivospemin along with standard treatments (nab-paclitaxel and gemcitabine), while others receive a placebo with the standard treatments. Neither the patients nor the doctors know who is receiving which treatment during the study.
  • What is the main goal of the Ivospemin clinical trial? The main goal of the trial is to compare overall survival between patients who receive Ivospemin and those who receive a placebo, both in combination with standard treatments for metastatic pancreatic cancer.
  • Who can participate in the Ivospemin clinical trial? The trial is for adults (18 years or older) with confirmed metastatic pancreatic ductal adenocarcinoma who haven't been treated for this condition before. Participants must meet certain health criteria and be willing to follow the study protocol.
  • What are some of the other things being measured in this trial? Besides overall survival, the trial is also looking at progression-free survival, how well tumors respond to treatment, quality of life changes, and the safety of Ivospemin. They're also exploring how the drug affects certain blood markers related to pancreatic cancer.

Ongoing Clinical Trials on Ivospemin

  • Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy Spain

Glossary

  • Metastatic Pancreatic Ductal Adenocarcinoma: A type of pancreatic cancer that has spread from the pancreas to other parts of the body. It starts in the ducts of the pancreas and is the most common form of pancreatic cancer.
  • Nab-paclitaxel: A chemotherapy drug used to treat various types of cancer, including pancreatic cancer. It's a form of paclitaxel bound to albumin, which helps deliver the drug to cancer cells.
  • Gemcitabine: A chemotherapy drug commonly used to treat pancreatic cancer and some other types of cancer. It works by interfering with cancer cell growth.
  • Overall Survival (OS): The length of time from the start of treatment until death from any cause. It's an important measure of how well a cancer treatment works.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable for a certain period after treatment.
  • Duration of Response (DoR): How long a tumor continues to respond to treatment without the cancer growing or spreading.
  • Quality of Life (QOL): A measure of a person's well-being and ability to carry out daily activities while dealing with an illness and its treatment.
  • CA19-9: A substance that can be found in the blood of some people with pancreatic cancer. It's often used as a tumor marker to help track how well treatment is working.
  • Circulating Tumor DNA (ctDNA): Small pieces of DNA from cancer cells that can be found in the blood. It can be used to monitor cancer progression or response to treatment.
  • Polyamine Metabolic Inhibitor: A type of drug that interferes with the metabolism of polyamines, which are molecules involved in cell growth and division. This interference may help slow down or stop cancer growth.

References

  1. http://clinicaltrials.eu/trial/study-of-sbp-101-nab-paclitaxel-and-gemcitabine-for-patients-with-metastatic-pancreatic-cancer/